Regorafenib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2401 publications
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2026
Functional Exploration of African Colorectal Cancer Patients Using Personalised Drosophila Avatars.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.
Journal: Oncotarget
Published: April 09, 2026
Overcoming Regorafenib Resistance in Colorectal Cancer: Synergistic Efficacy of Cilengitide in HT29 and WiDr Cells.
Journal: Medeniyet medical journal
Published: March 30, 2026
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.
Journal: ESMO gastrointestinal oncology
Published: March 19, 2026
Targeting SPP1 +TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer.
Journal: Journal for immunotherapy of cancer
Published: March 13, 2026
CEA and CA-19-9 Dynamics Associate with Survival in Regorafenib-Treated Metastatic Colorectal Cancer: A Real-World Analysis.
Journal: Journal of clinical medicine
Published: March 10, 2026
Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 03, 2026
Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence?
Journal: Clinical advances in hematology & oncology : H&O
Published: February 20, 2026
Editorial: Regorafenib Plus Nivolumab in Advanced Hepatocellular Carcinoma-A Step Toward Mechanism-Guided Second-Line Therapy.
Journal: Alimentary pharmacology & therapeutics
Published: February 19, 2026
RETRACTED: Refolo et al. Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells. Int. J. Mol. Sci. 2018, 19, 1518.
Journal: International journal of molecular sciences
Published: February 09, 2026
Regorafenib enhances anti-PDCD1/PD-1 therapeutic efficacy in colorectal cancer by promoting SQSTM1/p62-mediated CD274/PD-L1 degradation.
Journal: Autophagy
Published: February 08, 2026
Last Updated: 04/28/2026